CY1124282T1 - Συνδυασμος ενος ανταγωνιστη υποδοχεα 5-ητ6 και ενος αναστολεα ακετυλοχολινεστερασης για χρηση στην αντιμετωπιση της νοσου toy alzheimer σε εναν υποπληθυσμο ασθενων που φερει τα αλληλομορφα αροε4 - Google Patents
Συνδυασμος ενος ανταγωνιστη υποδοχεα 5-ητ6 και ενος αναστολεα ακετυλοχολινεστερασης για χρηση στην αντιμετωπιση της νοσου toy alzheimer σε εναν υποπληθυσμο ασθενων που φερει τα αλληλομορφα αροε4Info
- Publication number
- CY1124282T1 CY1124282T1 CY20211100328T CY211100328T CY1124282T1 CY 1124282 T1 CY1124282 T1 CY 1124282T1 CY 20211100328 T CY20211100328 T CY 20211100328T CY 211100328 T CY211100328 T CY 211100328T CY 1124282 T1 CY1124282 T1 CY 1124282T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alzheimer
- disease
- treatment
- apoe4
- receptor antagonist
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title abstract 2
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
- 239000003751 serotonin 6 antagonist Substances 0.000 title abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 108700028369 Alleles Proteins 0.000 abstract 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε ανταγωνιστές υποδοχέα 5-ΗΤ6 για χρήση στην αντιμετώπιση της νόσου του Alzheimer, όπου ο ασθενής της νόσου του Alzheimer φέρει ένα ή δύο αλληλόμορφα ApoE4, περιλαμβάνει χορήγηση μίας αποτελεσματικής δόσης ενός ανταγωνιστή υποδοχέα 5-ΗΤ6 για τη βελτίωση ή την αύξηση της επίδρασης ενός αναστολέα ακετυλοχολινεστεράσης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700313 | 2017-05-24 | ||
DKPA201700538 | 2017-09-29 | ||
PCT/EP2018/063402 WO2018215478A1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124282T1 true CY1124282T1 (el) | 2022-07-22 |
Family
ID=62235961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100328T CY1124282T1 (el) | 2017-05-24 | 2021-04-14 | Συνδυασμος ενος ανταγωνιστη υποδοχεα 5-ητ6 και ενος αναστολεα ακετυλοχολινεστερασης για χρηση στην αντιμετωπιση της νοσου toy alzheimer σε εναν υποπληθυσμο ασθενων που φερει τα αλληλομορφα αροε4 |
Country Status (22)
Country | Link |
---|---|
US (1) | US11464759B2 (el) |
EP (1) | EP3630098B1 (el) |
JP (1) | JP7167065B2 (el) |
KR (1) | KR20200007795A (el) |
CN (1) | CN111032038A (el) |
AU (1) | AU2018272883B2 (el) |
BR (1) | BR112019001145A2 (el) |
CA (1) | CA3063968A1 (el) |
CY (1) | CY1124282T1 (el) |
DK (1) | DK3630098T3 (el) |
ES (1) | ES2869128T3 (el) |
HR (1) | HRP20210634T1 (el) |
HU (1) | HUE053636T2 (el) |
LT (1) | LT3630098T (el) |
MX (1) | MX2019013912A (el) |
PL (1) | PL3630098T3 (el) |
PT (1) | PT3630098T (el) |
RS (1) | RS61704B1 (el) |
SG (1) | SG11201909895UA (el) |
SI (1) | SI3630098T1 (el) |
WO (1) | WO2018215478A1 (el) |
ZA (1) | ZA201907525B (el) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1379239B1 (en) | 2001-03-29 | 2007-09-12 | Eli Lilly And Company | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor |
CN1681941A (zh) * | 2002-08-07 | 2005-10-12 | 诺瓦提斯公司 | 基于ApoE基因型治疗痴呆的方法 |
JP5153870B2 (ja) | 2007-05-22 | 2013-02-27 | 大塚製薬株式会社 | カルボスチリル誘導体およびドネペジルを含むアルツハイマー病治療剤 |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
RU2369600C1 (ru) | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
PL2419104T3 (pl) | 2009-04-13 | 2018-04-30 | Theravance Biopharma R&D Ip, Llc | Kombinacje agonistów receptora 5-HT4 i inhibitorów acetylocholinoesterazy do leczenia zaburzeń poznawczych |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
US20160038484A1 (en) * | 2013-04-03 | 2016-02-11 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
WO2016179569A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
TW201806621A (zh) * | 2016-04-26 | 2018-03-01 | H 朗德貝克公司 | 乙醯膽鹼酯酶抑制劑和艾達魯吡啶用於在帕金森氏病患者中減少跌倒之用途 |
US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
-
2018
- 2018-05-22 JP JP2019564834A patent/JP7167065B2/ja active Active
- 2018-05-22 PL PL18726791T patent/PL3630098T3/pl unknown
- 2018-05-22 HU HUE18726791A patent/HUE053636T2/hu unknown
- 2018-05-22 LT LTEP18726791.9T patent/LT3630098T/lt unknown
- 2018-05-22 PT PT187267919T patent/PT3630098T/pt unknown
- 2018-05-22 SG SG11201909895U patent/SG11201909895UA/en unknown
- 2018-05-22 CN CN201880033314.8A patent/CN111032038A/zh active Pending
- 2018-05-22 ES ES18726791T patent/ES2869128T3/es active Active
- 2018-05-22 BR BR112019001145-5A patent/BR112019001145A2/pt active Search and Examination
- 2018-05-22 EP EP18726791.9A patent/EP3630098B1/en active Active
- 2018-05-22 WO PCT/EP2018/063402 patent/WO2018215478A1/en active Application Filing
- 2018-05-22 CA CA3063968A patent/CA3063968A1/en active Pending
- 2018-05-22 AU AU2018272883A patent/AU2018272883B2/en active Active
- 2018-05-22 SI SI201830258T patent/SI3630098T1/sl unknown
- 2018-05-22 KR KR1020197032218A patent/KR20200007795A/ko active IP Right Grant
- 2018-05-22 DK DK18726791.9T patent/DK3630098T3/da active
- 2018-05-22 MX MX2019013912A patent/MX2019013912A/es unknown
- 2018-05-22 RS RS20210449A patent/RS61704B1/sr unknown
- 2018-05-23 US US15/987,449 patent/US11464759B2/en active Active
-
2019
- 2019-11-13 ZA ZA2019/07525A patent/ZA201907525B/en unknown
-
2021
- 2021-04-14 CY CY20211100328T patent/CY1124282T1/el unknown
- 2021-04-22 HR HRP20210634TT patent/HRP20210634T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018215478A1 (en) | 2018-11-29 |
SG11201909895UA (en) | 2019-11-28 |
CN111032038A (zh) | 2020-04-17 |
BR112019001145A2 (pt) | 2019-04-30 |
HUE053636T2 (hu) | 2021-07-28 |
RU2019135609A (ru) | 2021-06-24 |
US11464759B2 (en) | 2022-10-11 |
KR20200007795A (ko) | 2020-01-22 |
PL3630098T3 (pl) | 2021-09-06 |
RU2019135609A3 (el) | 2021-08-23 |
RS61704B1 (sr) | 2021-05-31 |
CA3063968A1 (en) | 2018-11-29 |
JP2020520964A (ja) | 2020-07-16 |
ZA201907525B (en) | 2022-02-23 |
EP3630098A1 (en) | 2020-04-08 |
JP7167065B2 (ja) | 2022-11-08 |
LT3630098T (lt) | 2021-05-25 |
DK3630098T3 (da) | 2021-04-26 |
HRP20210634T1 (hr) | 2021-05-28 |
US20180353477A1 (en) | 2018-12-13 |
MX2019013912A (es) | 2020-01-21 |
AU2018272883B2 (en) | 2024-02-15 |
SI3630098T1 (sl) | 2021-07-30 |
EP3630098B1 (en) | 2021-03-24 |
ES2869128T3 (es) | 2021-10-25 |
PT3630098T (pt) | 2021-04-21 |
AU2018272883A1 (en) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124446T1 (el) | Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης | |
CY1125202T1 (el) | Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο hiv | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1121062T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
CY1120452T1 (el) | Παραγωγο αμιδιου πυραζολης | |
CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
CY1122892T1 (el) | Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
CY1117831T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
CY1123013T1 (el) | Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης | |
CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης | |
CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
CY1123644T1 (el) | Τριπλος συνδυασμος καθαρων ανταγωνιστων του υποδοχεα 5-ητ6, αναστολεων της ακετυλοχολινεστερασης και του ανταγωνιστη του υποδοχεα nmda |